================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 22, 2003
Medicis Pharmaceutical Corporation
(Exact Name of Registrant as Specified in Charter)
Delaware 0-18443 52-1574808
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
8125 North Hayden Road
Scottsdale,Arizona 85258-2463
(Address of Principal Executive (Zip Code)
Offices)
Registrant's telephone number, including area code: (602) 808-8800
N/A
-----------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
================================================================================
Item 7. Financial Statements and Exhibits
(a) Financial Statements of Business Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits.
99.1 Copy of press release, dated April 22, 2003, issued by Medicis
Pharmaceutical Corporation
Item 9. Regulation FD Disclosure
On April 22, 2003, Medicis Pharmaceutical Corporation issued a press
release summarizing its third quarter 2003 financial results. A copy of the
press release appears as Exhibit 99.1 to this Current Report and is incorporated
herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDICIS PHARMACEUTICAL
CORPORATION
(Registrant)
Date: April 23, 2003 /s/ Mark A. Prygocki, Sr.
---------------------------------
---------------------------------
Name: Mark A. Prygocki, Sr.
Title: Executive Vice President,
Chief Financial Officer,
Corporate Secretary and
Treasurer
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
--------- -----------------------------------------------------------
99.1 Copy of press release, dated April 22, 2003, issued by
Medicis Pharmaceutical Corporation.